{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T21:58:33Z","timestamp":1783547913783,"version":"3.55.0"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Nitto Foundation"},{"DOI":"10.13039\/501100005936","name":"CASIO SCIENCE PROMOTION FOUNDATION","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005936","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100006062","name":"Foundation for Promotion of Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"KAKENHI","doi-asserted-by":"publisher","award":["23K14361"],"award-info":[{"award-number":["23K14361"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"KAKENHI","doi-asserted-by":"publisher","award":["24K18315"],"award-info":[{"award-number":["24K18315"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Cancer cachexia reduces chemotherapy efficacy in patients with metastatic urothelial carcinoma (mUC). Anamorelin improves cancer cachexia by increasing serum insulin-like growth factor 1 (IGF-1). The aim of this study was to evaluate the efficacy and safety of anamorelin in patients with mUC.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A total of 38 patients with mUC who received platinum-based chemotherapy were enrolled in an interventional prospective study. Patients were randomized to anamorelin (Ana; n\u2005=\u200520) or control (n\u2005=\u200518) groups. The primary endpoint was the change in prealbumin. Secondary endpoints were changes in albumin, IGF-1, body weight, skeletal muscle mass index (SMI), interleukin-6 (IL-6) and median overall survival (mOS).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Changes in prealbumin, albumin, body weight, and SMI were similar between groups. Compared to control, serum IGF-1 levels in the anamorelin-treated group were higher after 1 week (P\u2005&amp;lt;\u2005.05). Changes in IGF-1 and SMI positively correlated in the anamorelin group (R\u2005=\u20050.61, P\u2005&amp;lt;\u2005.05). When the anamorelin group was divided into 2 groups by the median serum IGF-1 level after 1 week (Ana-IGF-1 high and Ana-IGF-1 low groups), the SMI in the latter group showed a decreased tendency (P\u2005=\u2005.14). The Ana-IGF-1 low group showed significantly higher IL-6 levels (P\u2005&amp;lt;\u2005.05) at baseline and significantly shorter mOS compared to the Ana-IGF-1 high group (P\u2005&amp;lt;\u2005.05). Treatment-related adverse events were comparable between the 2 groups (any grade: 100% vs 100%; grade \u22653: 88.9% vs 90.0%).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Anamorelin was well tolerated in patients with mUC. A higher serum IGF-1 level might be associated with anamorelin efficacy; however, a larger study is needed to confirm this.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyaf167","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T22:17:37Z","timestamp":1751408257000},"source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of anamorelin in patients with metastatic urothelial carcinoma receiving systemic chemotherapy: a randomized controlled study"],"prefix":"10.1093","volume":"30","author":[{"given":"Kunihiro","family":"Odagiri","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmaceutics, Nagoya City University Graduate School of Medical Sciences , Nagoya ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihisa","family":"Mimura","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmaceutics, Nagoya City University Graduate School of Medical Sciences , Nagoya ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7638-6048","authenticated-orcid":false,"given":"Taku","family":"Naiki","sequence":"additional","affiliation":[{"name":"Department of Nephro-urology, Nagoya City University Graduate School of Medical Sciences , Nagoya ,","place":["Japan"]},{"name":"Department of Urology, Nagoya City University West Medical Center , Nagoya ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiko","family":"Tasaki","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmaceutics, Nagoya City University Graduate School of Medical Sciences , Nagoya ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Sugiyama","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmaceutics, Nagoya City University Graduate School of Medical Sciences , Nagoya ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0828-2033","authenticated-orcid":false,"given":"Aya","family":"Naiki-Ito","sequence":"additional","affiliation":[{"name":"Department of Experimental Pathology and Tumor Biology, Nagoya City University Graduate School of Medical Sciences , Nagoya ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiki","family":"Etani","sequence":"additional","affiliation":[{"name":"Department of Nephro-urology, Nagoya City University Graduate School of Medical Sciences , Nagoya ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Nagai","sequence":"additional","affiliation":[{"name":"Department of Nephro-urology, Nagoya City University Graduate School of Medical Sciences , Nagoya ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiharu","family":"Morikawa","sequence":"additional","affiliation":[{"name":"Department of Nephro-urology, Nagoya City University Graduate School of Medical Sciences , Nagoya ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiko","family":"Shimizu","sequence":"additional","affiliation":[{"name":"Department of Nephro-urology, Nagoya City University Graduate School of Medical Sciences , Nagoya ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Aoki","sequence":"additional","affiliation":[{"name":"Department of Nephro-urology, Nagoya City University Graduate School of Medical Sciences , Nagoya ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masakazu","family":"Gonda","sequence":"additional","affiliation":[{"name":"Department of Nephro-urology, Nagoya City University Graduate School of Medical Sciences , Nagoya ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Yasui","sequence":"additional","affiliation":[{"name":"Department of Nephro-urology, Nagoya City University Graduate School of Medical Sciences , Nagoya ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Furukawa-Hibi","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmaceutics, Nagoya City University Graduate School of Medical Sciences , Nagoya ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,7,14]]},"reference":[{"key":"2025071500314132700_CIT0001","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"2025071500314132700_CIT0002","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","article-title":"Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study","volume":"18","author":"von der Masse","year":"2000","journal-title":"J Clin Oncol"},{"key":"2025071500314132700_CIT0003","doi-asserted-by":"crossref","first-page":"5634","DOI":"10.1200\/JCO.2008.21.4924","article-title":"Randomized phase II\/III trial assessing gemcitabine\/ carboplatin and methotrexate\/carboplatin\/vinblastine in patients with advanced urothelial cancer \u201cunfit\u201d for cisplatin-based chemotherapy: phase II--results of EORTC study 30986","volume":"27","author":"Santis","year":"2009","journal-title":"J Clin Oncol"},{"key":"2025071500314132700_CIT0004","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"key":"2025071500314132700_CIT0005","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N Engl J Med"},{"key":"2025071500314132700_CIT0006","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N Engl J Med"},{"key":"2025071500314132700_CIT0007","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"2025071500314132700_CIT0008","doi-asserted-by":"publisher","first-page":"790","DOI":"10.21037\/tau-22-805","article-title":"A narrative review of peripheral blood parameters for urothelial carcinoma treated with systemic antitumor drugs","volume":"12","author":"Nagai","year":"2023","journal-title":"Transl Androl Urol"},{"key":"2025071500314132700_CIT0009","doi-asserted-by":"publisher","first-page":"e2400209","DOI":"10.1200\/PO.24.00209","article-title":"Molecular subtypes are associated with clinical benefit in cisplatin-treated metastatic urothelial cancer patients","volume":"8","author":"Holmsten","year":"2024","journal-title":"JCO Precis Oncol"},{"key":"2025071500314132700_CIT0010","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.critrevonc.2012.02.001","article-title":"Clinical nutrition, body composition and oncology: a critical literature review of the synergies","volume":"84","author":"Jacquelin-Ravel","year":"2012","journal-title":"Crit Rev Oncol Hematol"},{"key":"2025071500314132700_CIT0011","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1097\/SPC.0000000000000580","article-title":"Cachexia and bladder cancer: clinical impact and management. Current opinion in supportive and palliative care","volume":"15","author":"Lokeshwar","year":"2021","journal-title":"Curr Opin Support Palliat Care"},{"key":"2025071500314132700_CIT0012","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","article-title":"Definition and classification of cancer cachexia: an international consensus","volume":"12","author":"Fearon","year":"2011","journal-title":"Lancet Oncol"},{"key":"2025071500314132700_CIT0013","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.clnu.2024.01.009","article-title":"Addressing cancer anorexia-cachexia in older patients: potential therapeutic strategies and molecular pathways","volume":"43","author":"Ispoglou","year":"2024","journal-title":"Clin Nutr"},{"key":"2025071500314132700_CIT0014","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1002\/jcsm.13073","article-title":"Molecular mechanisms of cancer cachexia-related loss of skeletal muscle mass: data analysis from preclinical and clinical studies","volume":"14","author":"Martin","year":"2023","journal-title":"J Cachexia Sarcopenia Nuscle"},{"key":"2025071500314132700_CIT0015","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1038\/nrc3829","article-title":"Cancer cachexia: understanding the molecular basis","volume":"14","author":"Argil\u00e9s","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"2025071500314132700_CIT0016","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1159\/000529203","article-title":"GNRI sustainability during one cycle of first-line chemotherapy as a prognostic indicator in patients with metastatic urothelial carcinoma","volume":"101","author":"Sugiyama","year":"2023","journal-title":"Oncology (Huntingt)"},{"key":"2025071500314132700_CIT0017","doi-asserted-by":"publisher","first-page":"2995","DOI":"10.31557\/APJCP.2019.20.10.2995","article-title":"Skeletal muscle mass reduction velocity as a simple prognostic indicator for patients with metastatic urothelial carcinoma receiving second-line chemotherapy","volume":"20","author":"Nagai","year":"2019","journal-title":"Asian Pac J Cancer Prev"},{"key":"2025071500314132700_CIT0018","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1159\/000539795","article-title":"Experience and prognostic analysis with avelumab switch maintenance treatment in metastatic urothelial carcinoma","volume":"103","author":"Isobe","year":"2025","journal-title":"Oncology (Huntingt)"},{"key":"2025071500314132700_CIT0019","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/ajco.13666","article-title":"Early cancer cachexia phenotype predicts survival of advanced urothelial cancer patients treated with pembrolizumab","volume":"18","author":"Yamamoto","year":"2022","journal-title":"Asia Pac J Clin Oncol"},{"key":"2025071500314132700_CIT0020","doi-asserted-by":"publisher","first-page":"475","DOI":"10.21873\/cdp.10351","article-title":"Cachexia index is a prognostic indicator in patients with metastatic urothelial carcinoma treated with systemic chemotherapy","volume":"4","author":"Mimura","year":"2024","journal-title":"Cancer Diagn Progn"},{"key":"2025071500314132700_CIT0021","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S1470-2045(15)00558-6","article-title":"Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials","volume":"17","author":"Temel","year":"2016","journal-title":"Lancet Oncol"},{"key":"2025071500314132700_CIT0022","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/cncr.31128","article-title":"Anamorelin (ONO-7643) for the treatment of patients with non-small cell lung cancer and cachexia: results from a randomized, double-blind, placebo-controlled, multicenter study of Japanese patients (ONO-7643-04)","volume":"24","author":"Katakami","year":"2018","journal-title":"Cancer"},{"key":"2025071500314132700_CIT0023","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1002\/cncr.34154","article-title":"A multicenter, open-label, single-arm study of anamorelin (ONO-7643) in patients with cancer cachexia and low body mass index","volume":"128","author":"Naito","year":"2022","journal-title":"Cancer"},{"key":"2025071500314132700_CIT0024","doi-asserted-by":"publisher","first-page":"4294","DOI":"10.1002\/cncr.32406","article-title":"A multicenter, open-label, single-arm study of anamorelin (ONO-7643) in advanced gastrointestinal cancer patients with cancer cachexia","volume":"125","author":"Hamauchi","year":"2019","journal-title":"Cancer"},{"key":"2025071500314132700_CIT0025","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"2025071500314132700_CIT0026","doi-asserted-by":"publisher","first-page":"3495","DOI":"10.1007\/s00520-016-3144-z","article-title":"Anamorelin (ONO-7643) in Japanese patients with non-small cell lung cancer and cachexia: results of a randomized phase 2 trial","volume":"24","author":"Takayama","year":"2016","journal-title":"Support Care Cancer"},{"key":"2025071500314132700_CIT0027","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"2025071500314132700_CIT0028","doi-asserted-by":"publisher","first-page":"1178224217726336","DOI":"10.1177\/1178224217726336","article-title":"Oncology update: anamorelin","volume":"10","author":"Prommer","year":"2017","journal-title":"Palliat Care"},{"key":"2025071500314132700_CIT0029","doi-asserted-by":"publisher","first-page":"789","DOI":"10.2217\/fon.14.14","article-title":"Anamorelin hydrochloride in the treatment of cancer anorexia-cachexia syndrome","volume":"10","author":"Currow","year":"2014","journal-title":"Future Oncol"},{"key":"2025071500314132700_CIT0030","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s40780-024-00359-5","article-title":"CONUT score as a predictor for anamorelin efficacy in patients with cancer cachexia receiving chemotherapy","volume":"10","author":"Fujii","year":"2024","journal-title":"J Pharm Health Care Sci"},{"key":"2025071500314132700_CIT0031","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1007\/s10637-024-01503-6","article-title":"Investigation of the association between therapeutic effectiveness of anamorelin and Glasgow prognostic score in patients with cancer cachexia: a competing risk analysis","volume":"43","author":"Shimomura","year":"2025","journal-title":"Invest New Drugs"},{"key":"2025071500314132700_CIT0032","doi-asserted-by":"publisher","first-page":"e7170","DOI":"10.1002\/cam4.7170","article-title":"Real-world safety and effectiveness of anamorelin for cancer cachexia: Interim analysis of post-marketing surveillance in Japan","volume":"13","author":"Takayama","year":"2024","journal-title":"Cancer Med"},{"key":"2025071500314132700_CIT0033","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/sj.cr.7290075","article-title":"Blockage of IGF-1R signaling sensitizes urinary bladder cancer cells to mitomycin-mediated cytotoxicity","volume":"11","author":"Sun","year":"2001","journal-title":"Cell Res"},{"key":"2025071500314132700_CIT0034","doi-asserted-by":"publisher","first-page":"51608","DOI":"10.18632\/oncotarget.9958","article-title":"Combined administration of fucoidan ameliorates tumor and chemotherapy-induced skeletal muscle atrophy in bladder cancer-bearing mice","volume":"7","author":"Chen","year":"2016","journal-title":"Oncotarget"},{"key":"2025071500314132700_CIT0035","doi-asserted-by":"crossref","first-page":"1444.e1","DOI":"10.1016\/j.urology.2014.01.028","article-title":"Insulin-like growth factor-1 receptor overexpression is associated with outcome in invasive urothelial carcinoma of urinary bladder: a retrospective study of patients treated using radical cystectomy","volume":"83","author":"Roibon","year":"2014","journal-title":"Urology"},{"key":"2025071500314132700_CIT0036","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00428-018-2468-0","article-title":"Insulin-like growth factor-1 receptor expression in upper tract urothelial carcinoma","volume":"474","author":"Eich","year":"2019","journal-title":"Virchows Arch"},{"key":"2025071500314132700_CIT0037","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/S1470-2045(14)71154-4","article-title":"Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trials","volume":"16","author":"Garcia","year":"2015","journal-title":"Lancet Oncol"},{"key":"2025071500314132700_CIT0038","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1007\/s00520-013-1800-0","article-title":"Effect of ghrelin and anamorelin (ONO-7643), a selective ghrelin receptor agonist, on tumor growth in a lung cancer mouse xenograft model. Supportive care in cancer","volume":"21","author":"Northrup","year":"2013","journal-title":"Suppot Care Cancer"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyaf167\/63638868\/oyaf167.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/7\/oyaf167\/63638868\/oyaf167.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/7\/oyaf167\/63638868\/oyaf167.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T04:31:51Z","timestamp":1752553911000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf167\/8180720"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":38,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7,4]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf167","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7]]},"published":{"date-parts":[[2025,7]]},"article-number":"oyaf167"}}